Emperra, a Potsdam, Germany-based startup that has created a digital diabetes management solution consisting of smart hardware and software, completed a US$3.1m Series B financing.
Backers included Robert Bosch Venture Capital GmbH (RBVC), a corporate venture capital company of the Bosch Group, and existing investors Peppermint VenturePartners and Investitionsbank des Landes Brandenburg.
The company intends to use the funds for further product development and international growth, predominantly in the United States and Europe.
Led by Dr. Christian Krey, CEO, Emperra has developed a digital diabetes management system called ESYSTA, which provides a full integration of all product components required to guide and monitor the patients like smart insulin pens (usable with all major insulin brands), blood glucose meter and corresponding CE-marked software like web-based portal and apps.
The therapy data can be shared among all stakeholders (patient, physicians, nurses, care givers including relatives) and displayed via multiple channels, including a web-based portal, smart TV, and apps.
In Germany, the product has already received reimbursement status from German health insurers, which means it is now available on prescription for any patient with diabetes.